Recursion Pharmaceuticals Inc vs Williams Companies Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B), while Williams Companies Inc trades at $72.29 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 48.9× Recursion Pharmaceuticals Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WMB | |
|---|---|---|
Market Cap | $1.81B | $88.45B |
Sector | Health | Energy |
52-Week High | $6.79 | $79.40 |
52-Week Low | $2.84 | $56.51 |
Enterprise Value | $1.33B | $119.07B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Williams Companies (WMB) trades at $71.85, up 2.06% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.50, slightly missing estimates, but raised full-year EBITDA guidance. Recent news highlights the $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast presence and supporting long-term growth targets. Financials show strong profitability with a 25.18% net income margin and robust cash flow from operations of $5.90 billion in 2025.
Outlook remains positive with analyst consensus favoring Buy ratings (79.41%) and a $87.14 price target, though risks include execution of acquisitions and debt levels. The stock offers a dividend yield supported by stable cash flows, positioning it for growth in energy infrastructure demand.
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →